Live

FierceBiotechPassage launches strategic review and 75% layoffs after gene therapy path blocked by FDA IlluminaFinal Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC Endpoints NewsFDA search for new CBER head focused on small group of final candidates FierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China BioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drug Endpoints NewsSupreme Court restores mifepristone access by mail Clinical OMICsBiomarker of Epigenetic Aging Could Signal Depression AmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.com FierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 win Samsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce Pharma NovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce Pharma FierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQvia

FierceBiotech May 4, 2026

‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and China

For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab but is being shaped by industrial policy. In a recent i...

For Jake Becraft, Ph.D., the future of America’s biomedical innovation isn’t just playing out in the lab but is being shaped by industrial policy. In a recent interview with Fierce Biotech, the Strand Therapeutics CEO warned that the U.S. faces a critical choice: either modernize its regulatory framework for early-stage clinical trials or risk losing the capabilities permanently.